BioSpace News Archive

As manufacturers across industry sectors pitch in to accelerate production of life-saving ventilator equipment, ZAGO Manufacturing is ready to meet heightened, global demand for its specialty high-tech sealing fasteners.

High EPA Levels Associated with Substantial Reductions in Multiple Cardiovascular Endpoints Including Heart Failure and Total Mortality

Rise in innovations to deal with zoonotic diseases is imparting growth to the autogenous vaccines market. Next-generation processes in biotechnology are also creating a favorable environment for the development of autogenous vaccines.

Persons with a substance use disorder (SUD) or history of SUD treatment will now have easier access to fully-informed, comprehensive healthcare with passage of the Protecting Jessica Grubb’s Legacy Act, included in the Coronavirus Aid, Relief, and Economic Security (CARES) Act passed by Congress and signed into law by the President on Friday, March 27.

Agilent Technologies, Inc. filed a supplement to its proxy statement with the Securities and Exchange Commission announcing a change of location for its previously adjourned annual meeting of stockholders.

With the significant burden COVID-19 is having on the healthcare systems and increased need for self-care solutions, Bayer announced a donation of one million products to support the health of underserved communities.

Due to overwhelming need, Banyan Medical Systems expands its TAP4H initiative to pledge up to $10 million to help hospital staff fight the COVID-19 outbreak

Viracor Eurofins announces the launch of Labs@HOME, a mobile phlebotomy service to aid in specimen collection for vital post-transplant testing directly from patient’s home.

Mersana Therapeutics, Inc. announced updated efficacy and safety data in patients with ovarian cancer and non-small cell lung cancer adenocarcinoma from its ongoing Phase 1 dose escalation study evaluating XMT-1536.

Neovasc Inc., a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, the Tiara™, and minimally invasive devices for the treatment of refractory angina, the Neovasc Reducer™ reported financial results for the fourth quarter and full year ending December 31, 2019.